WO2010103374A2 - Oily suspension containing probiotic bacteria for paediatric uses - Google Patents

Oily suspension containing probiotic bacteria for paediatric uses Download PDF

Info

Publication number
WO2010103374A2
WO2010103374A2 PCT/IB2010/000486 IB2010000486W WO2010103374A2 WO 2010103374 A2 WO2010103374 A2 WO 2010103374A2 IB 2010000486 W IB2010000486 W IB 2010000486W WO 2010103374 A2 WO2010103374 A2 WO 2010103374A2
Authority
WO
WIPO (PCT)
Prior art keywords
dsm
probiotical
streptococcus
thermophilus
lactobacillus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2010/000486
Other languages
French (fr)
Other versions
WO2010103374A8 (en
WO2010103374A9 (en
WO2010103374A3 (en
Inventor
Gian Paolo Strozzi
Luca Mogna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Probiotical SpA
Original Assignee
Probiotical SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN2010800162523A priority Critical patent/CN102438589A/en
Priority to BRPI1009208A priority patent/BRPI1009208A2/en
Priority to CA2754612A priority patent/CA2754612A1/en
Priority to US13/255,176 priority patent/US20120058095A1/en
Priority to EP10716405A priority patent/EP2405894A2/en
Priority to JP2011553543A priority patent/JP2012519727A/en
Priority to AU2010222618A priority patent/AU2010222618B2/en
Priority to RU2011139210/15A priority patent/RU2011139210A/en
Application filed by Probiotical SpA filed Critical Probiotical SpA
Publication of WO2010103374A2 publication Critical patent/WO2010103374A2/en
Publication of WO2010103374A3 publication Critical patent/WO2010103374A3/en
Anticipated expiration legal-status Critical
Publication of WO2010103374A8 publication Critical patent/WO2010103374A8/en
Publication of WO2010103374A9 publication Critical patent/WO2010103374A9/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
    • A23D9/013—Other fatty acid esters, e.g. phosphatides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A23P10/35—Encapsulation of particles, e.g. foodstuff additives with oils, lipids, monoglycerides or diglycerides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia

Definitions

  • Oily suspension containing probiotic bacteria for paediatric use Oily suspension containing probiotic bacteria for paediatric use .
  • the present invention refers to an oily suspension containing probiotic bacteria, particularly suitable for paediatric use.
  • a first disadvantage relates to the instability of the bacteria inside the composition.
  • the initial declared bacterial load for a given composition decays over time because of the lack of stability of the bacteria within it.
  • the initial bacterial load present in the starting product does not correspond, after a certain relatively brief lapse of time after the time of manufacture, to what is stated in the declaration on the label, because of the decay which occurs in the bacterial load.
  • a second disadvantage relates to the nature of the oil which not only affects the state of vitality of the bacteria but can condition their efficacy, once administered within the organism (in-vivo vitality and functionality) .
  • composition containing an oil and probiotic bacteria having an improved stability by comparison with the compositions presently available on the market.
  • the composition containing an oil and probiotic lactic bacteria to be prepared so as to maintain the bacteria in a good state of vitality and functionality.
  • the Applicant has responded to the above-mentioned needs by perfecting an oily suspension comprising at least one oil, edible and utilizable in human nutrition, and at least one probiotic micro-organism, as stated in the attached independent claim.
  • the suspension which is the subject of the present invention has applications in patients of paediatric age, as stated in the attached independent claim.
  • the Applicant has perfected a supplement having a composition which comprises a food matrix and probiotic micro-organisms .
  • Probiotic micro-organisms are live bacteria capable of producing a beneficial effect on the consumer when ingested in sufficient quantities and for a sufficient time.
  • Probiotics usually belong to the genera Lactobacillus, Bifidobacterium, Streptococcus, Lactococcus, Pediococcus, Propionibacterium, Leuconostoc and Saccharomyces .
  • the species endowed with probiotic activity are L. acidophilus, L. crispatus, L. gasseri, L. delbrueckii group, L. salivarius, L. casei, L. paracasei, L. plantarum group, L. rhamnosus, L. reuteri, L. brevis, L. buchneri, L. fermentum, L. fructivorans, L. ruminis, L. sakei and L. vaginalis .
  • Streptococcus thermophilus Pediococcus pentosaceous, Leuconostoc argentinum and mesenteroides , while the following belong to the genus Bifidobacterium: B. adolescentis, B. angulatum, B. bifidum, B. breve, B. catenulatum, B. infantis, B. lactis, B. longum and B. pseudocatenulatum.
  • the probiotics used in the preparation of the oily suspension in accordance with the present invention are selected from the group comprising the following species: L. acidophilus, L. crispatus, L. gasseri, L. delbrueckii group, L. salivarius, L. casei, L. paracasei, L. plantarum group, L. rhamnosus, L. reuteri, L. brevis, L. buchneri, L. fermentum, B. adolescentis, B. angulatum, B. bifidum, B. breve, B. catenulatum, B. infantis, B. lactis, B. longum, B. pseudocatenulatum and S. thermophilus .
  • the suspension comprises from one to six strains, preferably from two to four strains, even more preferably three strains selected from among the probiotic species mentioned above.
  • Table 1 shows, by way of example, a group of micro-organisms which have valid application in the context of the present invention.
  • the probiotic bacteria can be in solid form, in particular in the form of powder, dehydrated powder or lyophilized powder.
  • the oily suspension of the present invention is prepared according to techniques known to experts in the field.
  • a determinate quantity of oil is introduced into a container provided with stirring and heating means. Subsequently, the probiotic bacteria in solid form are added gradually, under stirring, avoiding the formation of lumps and agglomerates. When the addition of the bacteria is completed, the oily suspension is kept stirred for a time of between 1 and 30 minutes, possibly by means of gentle heating to a temperature of between 25°C and 40 0 C, preferably between 30 0 C and 35 0 C.
  • the probiotic bacteria can be utilized in micro-encapsulated form, i.e. coated with a composition containing at least one lipid, preferably of vegetable origin.
  • the microencapsulated bacteria are then added to the oil, with the same operative procedures as stated above.
  • the bacteria added to the oil can be in the form of micro-encapsulated bacteria and non-micro-encapsulated "naked" bacteria.
  • the probiotic bacteria are coated with a single coating of vegetable origin.
  • the probiotic microorganisms are coated with a first and a second coating of vegetable origin.
  • lipids of vegetable nature are selected from the group comprising the saturated vegetable fats having a melting point between 35 0 C and 75 0 C, preferably between 45 0 C and 65 0 C, advantageously between 50 0 C and 60 0 C.
  • saturated vegetable fats with a certain degree of hydrophilicity can be used, which can be selected from among the mono- and di-glycerids of saturated fatty acids, the esterified polyglycerols with saturated fatty acids and the free saturated fatty acids.
  • the saturated fatty acids can be selected from the group comprising between 8 and 32 carbon atoms, preferably between 12 and 28 carbon atoms, even more preferably between 16 and 24 carbon atoms.
  • the coating lipid is selected from the group comprising polyglyceryl distearate (commercial name Plurol Stearique WL 1009) , glyceryl palmitostearate (commercial name Precirol Ato 5) , saturated fatty acids (commercial name Revel C) , hydrogenated vegetable fats of non-lauric origin and hydrogenated palm fats or stearin.
  • the probiotic bacteria are coated with a single coating (mono-coated) .
  • a single coating with the same lipid is carried out.
  • the single coating consists of polyglyceryl distearate or polyglycerol ester of vegetable origin or polyglyceryl-6-distearate CAS 61725-93-7 (commercial name Plurol Stearique WL1009) .
  • the ratio by weight between lyophilized micro-organism and the lipid coating substance which coats them is 50:50 or 40:60.
  • the probiotic bacteria are double-coated.
  • a double coating is carried out, in succession, with two lipids different from each other (double coating: a first and a second coating separate from each other) .
  • the two lipids are sprayed onto the lyophilized bacteria in succession, i.e. a double covering is applied to the lyophilate: the first with the hydrogenated palm fat and the second with the glycerol dipalmitostearate in the ratio 3:1 to each other.
  • the bacteria preferably in micro-encapsulated form, can be micro-encapsulated using the ordinary techniques known to experts in the field.
  • a fluid bed technique can be used (for example, top-spray or bottom- spray) , in which coating materials of a lipid nature are used.
  • a double coating of the cells ensures better sealing of the bacteria from the environment, producing a continuous film without pores communicating with the outside.
  • This wrapper must open at intestinal level to release the bacteria and allow them to colonize.
  • the lipids selected are in fact resistant to acid pH, so that the coating remains intact in the stomach, but sensitive to even slightly basic pH, so as to allow the formation of holes in the coating during its passage through the intestine.
  • the oily suspension contains the bacteria in a quantity less than or equal to 30% by weight, between 0.05% and 20% by weight, compared with the total weight of the suspension; preferably in a quantity of between 0.5% and 10%; even more preferably in a quantity of between 1.5% and 5% by weight, compared with the total weight of the suspension.
  • the oily suspension comprises at least one oil, edible and suitable for being administered to patients of paediatric age, said oil being selected from the group comprising: olive oil, maize oil, soya oil, linseed oil, groundnut oil, sesame oil, fish oil and rice oil.
  • said oils are of biological grade and can include in their preparation a refining stage and/or a cold pressing stage.
  • the oily suspension comprises at least one oil in a quantity greater than or equal to 70% by weight, compared with the total weight of the suspension, preferably in a quantity of between 75% and 95% by weight, advantageously at least 90% by weight .
  • the oily suspension contains only olive oil or olive oil mixed with maize oil and/or soya oil and/or linseed oil.
  • the olive oil is extravirgin and of Bio grade .
  • the oily suspension comprises furthermore at least one finely-divided food compound, selected from the group comprising silica, silicon dioxide, silica gel, colloidal silica, precipitated silica, syloid 244, talc, magnesium silicate, magnesium oxide, magnesium carbonate, calcium silicate, lecithin, mono- or di-glycerids such as glyceril monostearate, glyceril monooleate, plurol- oleic acid, starch, modified starches, Konjac gum, xanthan gum, gelIan gum, carrageenan.
  • at least one finely-divided food compound selected from the group comprising silica, silicon dioxide, silica gel, colloidal silica, precipitated silica, syloid 244, talc, magnesium silicate, magnesium oxide, magnesium carbonate, calcium silicate, lecithin, mono- or di-glycerids such as glyceril monostearate, glyceril monooleate, plu
  • Said material is present in a quantity of between 0.1% and 15% by weight, compared with the total weight of the suspension, preferably of between 5% and 10% by weight, compared with the total weight of the suspension.
  • the preparation procedure provides that a determinate quantity of oil has added to it the finely-divided food material, for example silicon dioxide, under stirring and heating the oil to about 60 0 C, until it is completely dissolved.
  • the silicon dioxide can be added cold; dissolving will however require more time.
  • the suspension is allowed to cool from 60 0 C to room temperature.
  • the lyophilate is weighed and added to the suspension under stirring, until complete and homogeneous dispersion is achieved.
  • the oily suspension can furthermore comprise at least one prebiotic fibre and/or at least one carbohydrate with bifidogenic action.
  • the prebiotic fibres and the carbohydrates have a double function. The first is to serve a prebiotic purpose. The second is to serve a technological purpose as a thickener and stabilizer.
  • the prebiotic fibres and carbohydrates are selected for example from among inulin, fructo-oligosaccharides (FOS) , galacto- and transgalacto-oligosaccharides (GOS and TOS) , gluco-oligosaccharides (GOS ⁇ ) , xylo-oligosaccharides (XOS) , chitosan-oligosaccharides (COS) , soya-oligosaccharides (SOS) , isomalto-oligosaccharides (IMOS) , maltodextrin, resistant starch, pectin, psyllium, arabino-galactanes , gluco- mannanes, galacto-mannanes, xylanes, lactosaccharose, lactulose, lactitol and various other types of gums, acacia fibre, carruba fibre, oat fibre, bamboo fibre, citrus fibres and, in general, fibres containing
  • said prebiotic fibres and carbohydrates are selected from among gluco- oligosaccharides (GOS ⁇ ) , fructo-oligosaccharides (FOS) , inulin and/or maltodextrin.
  • the composition comprises at least one prebiotic fibre selected from among those mentioned above and/or suitable mixtures between them in any relative percentage.
  • the quantity of prebiotic fibres and/or of carbohydrates with bifidogenic action, if present, is between 0.5% and 25% by weight, preferably between 1% and 20% and even more preferably between 5% and 10%, compared with the total weight of the suspension. In this case the result is a suspension with symbiotic activity.
  • the suspension can also comprise other active ingredients and/or components such as vitamins, minerals, bioactive peptides, substances with anti-oxidizing action, hypocholesterolaemic agent, hypoglycaemic agent, antiinflammatory and anti- sweetening agents in a quantity generally of between 0.001% and 10% by weight, preferably between 0.5% and 5% by weight, always depending on the type of active component and its recommended daily dose if any, compared with the total weight of the suspension.
  • active ingredients and/or components such as vitamins, minerals, bioactive peptides, substances with anti-oxidizing action, hypocholesterolaemic agent, hypoglycaemic agent, antiinflammatory and anti- sweetening agents in a quantity generally of between 0.001% and 10% by weight, preferably between 0.5% and 5% by weight, always depending on the type of active component and its recommended daily dose if any, compared with the total weight of the suspension.
  • An object of the present invention is the oily suspension for use as a medicament for the treatment of intestinal disturbances such as for example colic in paediatric patients.
  • a further object of the present invention is the use of said strains of micro-organisms for the preparation of a medicament or supplement for the treatment of certain intestinal disturbances such as for example colic in paediatric patients.
  • the Applicant has tested the decay of the bacterial load in the following oils: Olive oil, maize oil, cold-pressed soya oil and cold-pressed linseed oil.
  • the strain used was LMG P-21380 ⁇ Lactobacillus paracasei LPC 00) , in lyophilized form, having an initial load of 400 MLD/g.
  • a mixture of the pure lyophilate in oil was prepared so as to have 1 MLD/lOml of oil (2.5mg in 10ml of oil) .
  • Table 3 shows: 1) Bio olive oil, 2) maize oil, 3) sunflower oil, 4) cold-pressed soya oil, 5) cold- pressed linseed oil .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

The present invention refers to an oily suspension containing probiotic bacteria, particularly suitable for paediatric use.

Description

DESCRIPTION
Oily suspension containing probiotic bacteria for paediatric use .
The present invention refers to an oily suspension containing probiotic bacteria, particularly suitable for paediatric use.
It is well-known that there are on the market liquid compositions containing an oil and lactic bacteria for the treatment of a number of intestinal disturbances such as, for example, colic in paediatric patients.
Said compositions, however, have a number of disadvantages which limit their use.
A first disadvantage relates to the instability of the bacteria inside the composition.
In practice, lactic bacteria immersed in oil suffer from a lack of stability which causes a decay in the bacterial load over time.
The initial declared bacterial load for a given composition decays over time because of the lack of stability of the bacteria within it.
Therefore, the initial bacterial load present in the starting product does not correspond, after a certain relatively brief lapse of time after the time of manufacture, to what is stated in the declaration on the label, because of the decay which occurs in the bacterial load.
A second disadvantage relates to the nature of the oil which not only affects the state of vitality of the bacteria but can condition their efficacy, once administered within the organism (in-vivo vitality and functionality) .
Finally, there are also some considerations to make on the stability of the composition itself. In practice, after a certain interval of time lactic bacteria immersed in oil can give rise to precipitations or aggregations, with the subsequent formation of a sediment. These phenomena can alter the "shelf life" of the composition.
The necessity therefore remains of having available a liquid composition containing an oil and probiotic bacteria, having an improved stability by comparison with the compositions presently available on the market. In practice, it is important to prepare a composition containing an oil and probiotic bacteria in which the bacterial load initially present is not subject to excessive decay over time leading to a drastic reduction in said bacterial load. Finally, it is necessary for the composition containing an oil and probiotic lactic bacteria to be prepared so as to maintain the bacteria in a good state of vitality and functionality.
The Applicant has responded to the above-mentioned needs by perfecting an oily suspension comprising at least one oil, edible and utilizable in human nutrition, and at least one probiotic micro-organism, as stated in the attached independent claim.
The suspension which is the subject of the present invention has applications in patients of paediatric age, as stated in the attached independent claim.
In particular, the Applicant has perfected a supplement having a composition which comprises a food matrix and probiotic micro-organisms .
Embodiments of the present invention are set forth in the detailed description which follows, in exemplary form and therefore not limiting the range of the present invention. Probiotic micro-organisms are live bacteria capable of producing a beneficial effect on the consumer when ingested in sufficient quantities and for a sufficient time.
Probiotics usually belong to the genera Lactobacillus, Bifidobacterium, Streptococcus, Lactococcus, Pediococcus, Propionibacterium, Leuconostoc and Saccharomyces .
In the sphere of lactic bacteria of the genus Lactobacillus, the species endowed with probiotic activity are L. acidophilus, L. crispatus, L. gasseri, L. delbrueckii group, L. salivarius, L. casei, L. paracasei, L. plantarum group, L. rhamnosus, L. reuteri, L. brevis, L. buchneri, L. fermentum, L. fructivorans, L. ruminis, L. sakei and L. vaginalis .
Among the other lactic bacteria we recall Streptococcus thermophilus, Pediococcus pentosaceous, Leuconostoc argentinum and mesenteroides , while the following belong to the genus Bifidobacterium: B. adolescentis, B. angulatum, B. bifidum, B. breve, B. catenulatum, B. infantis, B. lactis, B. longum and B. pseudocatenulatum.
The probiotics used in the preparation of the oily suspension in accordance with the present invention are selected from the group comprising the following species: L. acidophilus, L. crispatus, L. gasseri, L. delbrueckii group, L. salivarius, L. casei, L. paracasei, L. plantarum group, L. rhamnosus, L. reuteri, L. brevis, L. buchneri, L. fermentum, B. adolescentis, B. angulatum, B. bifidum, B. breve, B. catenulatum, B. infantis, B. lactis, B. longum, B. pseudocatenulatum and S. thermophilus .
In a preferred embodiment of the invention, the suspension comprises from one to six strains, preferably from two to four strains, even more preferably three strains selected from among the probiotic species mentioned above. Table 1 shows, by way of example, a group of micro-organisms which have valid application in the context of the present invention.
All the strains have been deposited in accordance with the
Treaty of Budapest and are accessible to the public on request from the competent Depositing Authority.
The probiotic bacteria can be in solid form, in particular in the form of powder, dehydrated powder or lyophilized powder.
The oily suspension of the present invention is prepared according to techniques known to experts in the field.
In practice, a determinate quantity of oil is introduced into a container provided with stirring and heating means. Subsequently, the probiotic bacteria in solid form are added gradually, under stirring, avoiding the formation of lumps and agglomerates. When the addition of the bacteria is completed, the oily suspension is kept stirred for a time of between 1 and 30 minutes, possibly by means of gentle heating to a temperature of between 25°C and 400C, preferably between 300C and 350C.
In a preferred embodiment of the present invention, the probiotic bacteria can be utilized in micro-encapsulated form, i.e. coated with a composition containing at least one lipid, preferably of vegetable origin. The microencapsulated bacteria are then added to the oil, with the same operative procedures as stated above.
In another embodiment of the present invention, the bacteria added to the oil can be in the form of micro-encapsulated bacteria and non-micro-encapsulated "naked" bacteria.
In a preferred embodiment, the probiotic bacteria are coated with a single coating of vegetable origin.
In another preferred embodiment, the probiotic microorganisms are coated with a first and a second coating of vegetable origin. In a preferred embodiment, lipids of vegetable nature are selected from the group comprising the saturated vegetable fats having a melting point between 350C and 750C, preferably between 450C and 650C, advantageously between 500C and 600C.
In a preferred embodiment, saturated vegetable fats with a certain degree of hydrophilicity can be used, which can be selected from among the mono- and di-glycerids of saturated fatty acids, the esterified polyglycerols with saturated fatty acids and the free saturated fatty acids.
The saturated fatty acids can be selected from the group comprising between 8 and 32 carbon atoms, preferably between 12 and 28 carbon atoms, even more preferably between 16 and 24 carbon atoms.
Advantageously, the coating lipid is selected from the group comprising polyglyceryl distearate (commercial name Plurol Stearique WL 1009) , glyceryl palmitostearate (commercial name Precirol Ato 5) , saturated fatty acids (commercial name Revel C) , hydrogenated vegetable fats of non-lauric origin and hydrogenated palm fats or stearin.
In a first embodiment, the probiotic bacteria are coated with a single coating (mono-coated) . In practice, a single coating with the same lipid is carried out.
Advantageously, the single coating consists of polyglyceryl distearate or polyglycerol ester of vegetable origin or polyglyceryl-6-distearate CAS 61725-93-7 (commercial name Plurol Stearique WL1009) .
In a preferred embodiment, the ratio by weight between lyophilized micro-organism and the lipid coating substance which coats them is 50:50 or 40:60.
In a second preferred embodiment, the probiotic bacteria are double-coated. In practice, a double coating is carried out, in succession, with two lipids different from each other (double coating: a first and a second coating separate from each other) .
Advantageously, the two lipids are selected from the group comprising a hydrogenated palm fat (Tm=60°C) and a glycerol dipalmitostearate (Tm=57-60°C) . The two lipids are sprayed onto the lyophilized bacteria in succession, i.e. a double covering is applied to the lyophilate: the first with the hydrogenated palm fat and the second with the glycerol dipalmitostearate in the ratio 3:1 to each other.
The bacteria, preferably in micro-encapsulated form, can be micro-encapsulated using the ordinary techniques known to experts in the field. For example, a fluid bed technique can be used (for example, top-spray or bottom- spray) , in which coating materials of a lipid nature are used.
In a first embodiment, two lipids selected from between a hydrogenated palm fat (Tm=60°C) and a glycerol dipalmitostearate (Tm=57-60°C) are sprayed onto the lyophilate in succession, i.e. a double covering is applied to the lyophilate: the first with the hydrogenated palm fat and the second with the glycerol dipalmitostearate in the ratio 3:1 to each other. A double coating of the cells ensures better sealing of the bacteria from the environment, producing a continuous film without pores communicating with the outside. This wrapper, however, must open at intestinal level to release the bacteria and allow them to colonize. The lipids selected are in fact resistant to acid pH, so that the coating remains intact in the stomach, but sensitive to even slightly basic pH, so as to allow the formation of holes in the coating during its passage through the intestine.
The oily suspension contains the bacteria in a quantity less than or equal to 30% by weight, between 0.05% and 20% by weight, compared with the total weight of the suspension; preferably in a quantity of between 0.5% and 10%; even more preferably in a quantity of between 1.5% and 5% by weight, compared with the total weight of the suspension.
The oily suspension comprises at least one oil, edible and suitable for being administered to patients of paediatric age, said oil being selected from the group comprising: olive oil, maize oil, soya oil, linseed oil, groundnut oil, sesame oil, fish oil and rice oil.
Advantageously, said oils are of biological grade and can include in their preparation a refining stage and/or a cold pressing stage.
The oily suspension comprises at least one oil in a quantity greater than or equal to 70% by weight, compared with the total weight of the suspension, preferably in a quantity of between 75% and 95% by weight, advantageously at least 90% by weight .
Advantageously, the oily suspension contains only olive oil or olive oil mixed with maize oil and/or soya oil and/or linseed oil. Advantageously, the olive oil is extravirgin and of Bio grade .
In a preferred embodiment, the oily suspension comprises furthermore at least one finely-divided food compound, selected from the group comprising silica, silicon dioxide, silica gel, colloidal silica, precipitated silica, syloid 244, talc, magnesium silicate, magnesium oxide, magnesium carbonate, calcium silicate, lecithin, mono- or di-glycerids such as glyceril monostearate, glyceril monooleate, plurol- oleic acid, starch, modified starches, Konjac gum, xanthan gum, gelIan gum, carrageenan.
Said material is present in a quantity of between 0.1% and 15% by weight, compared with the total weight of the suspension, preferably of between 5% and 10% by weight, compared with the total weight of the suspension. In this case the preparation procedure provides that a determinate quantity of oil has added to it the finely-divided food material, for example silicon dioxide, under stirring and heating the oil to about 600C, until it is completely dissolved.
Alternatively, the silicon dioxide can be added cold; dissolving will however require more time.
Subsequently, the suspension is allowed to cool from 600C to room temperature. Next, the lyophilate is weighed and added to the suspension under stirring, until complete and homogeneous dispersion is achieved.
An example of a suspension comprising oil, probiotic bacteria and a finely-divided material is shown in Table 2.
In a preferred embodiment, the oily suspension can furthermore comprise at least one prebiotic fibre and/or at least one carbohydrate with bifidogenic action. The prebiotic fibres and the carbohydrates have a double function. The first is to serve a prebiotic purpose. The second is to serve a technological purpose as a thickener and stabilizer.
The prebiotic fibres and carbohydrates are selected for example from among inulin, fructo-oligosaccharides (FOS) , galacto- and transgalacto-oligosaccharides (GOS and TOS) , gluco-oligosaccharides (GOSα) , xylo-oligosaccharides (XOS) , chitosan-oligosaccharides (COS) , soya-oligosaccharides (SOS) , isomalto-oligosaccharides (IMOS) , maltodextrin, resistant starch, pectin, psyllium, arabino-galactanes , gluco- mannanes, galacto-mannanes, xylanes, lactosaccharose, lactulose, lactitol and various other types of gums, acacia fibre, carruba fibre, oat fibre, bamboo fibre, citrus fibres and, in general, fibres containing a soluble portion and an insoluble portion, in variable ratios to each other.
In a preferred embodiment of the invention, said prebiotic fibres and carbohydrates are selected from among gluco- oligosaccharides (GOSα) , fructo-oligosaccharides (FOS) , inulin and/or maltodextrin.
In a preferred embodiment of the invention, the composition comprises at least one prebiotic fibre selected from among those mentioned above and/or suitable mixtures between them in any relative percentage.
The quantity of prebiotic fibres and/or of carbohydrates with bifidogenic action, if present, is between 0.5% and 25% by weight, preferably between 1% and 20% and even more preferably between 5% and 10%, compared with the total weight of the suspension. In this case the result is a suspension with symbiotic activity.
Furthermore, the suspension can also comprise other active ingredients and/or components such as vitamins, minerals, bioactive peptides, substances with anti-oxidizing action, hypocholesterolaemic agent, hypoglycaemic agent, antiinflammatory and anti- sweetening agents in a quantity generally of between 0.001% and 10% by weight, preferably between 0.5% and 5% by weight, always depending on the type of active component and its recommended daily dose if any, compared with the total weight of the suspension.
An object of the present invention is the oily suspension for use as a medicament for the treatment of intestinal disturbances such as for example colic in paediatric patients.
A further object of the present invention is the use of said strains of micro-organisms for the preparation of a medicament or supplement for the treatment of certain intestinal disturbances such as for example colic in paediatric patients.
The Applicant has tested the decay of the bacterial load in the following oils: Olive oil, maize oil, cold-pressed soya oil and cold-pressed linseed oil. The strain used was LMG P-21380 {Lactobacillus paracasei LPC 00) , in lyophilized form, having an initial load of 400 MLD/g. A mixture of the pure lyophilate in oil was prepared so as to have 1 MLD/lOml of oil (2.5mg in 10ml of oil) . The results are reported in Table 3. Table 3 shows: 1) Bio olive oil, 2) maize oil, 3) sunflower oil, 4) cold-pressed soya oil, 5) cold- pressed linseed oil .
TO= Start time, E-05= lxlO"5' E-09= lxlθ~9' E-14= IxIO"14' Bn= Billion

Claims

1. An oily suspension, particularly for paediatric use, comprising : at least one food oil selected from the group comprising: olive oil, maize oil, soya oil, linseed oil, groundnut oil, sesame oil, fish oil and rice oil, said at least one oil being present in a quantity greater than or equal to 70% by weight, compared with the total weight of the suspension, and at least one strain of micro-organism selected from the group consisting of the following species: L. acidophilus, L. crispatus, L. gasseri , L. delbrueckii group, L. salivarius, L. casei , L. paracasei, L. plantaruw group, L. rhamnosus, L. reuteri, L. brevis, L. buchneri , L. fermentum, B. adolescentis, B. angulatum, B. bifidum, B. breve, B. catenulatum, B. infantis , B. lactis, B. longum, B. pseudocatenulatum and S. thermophilus , wherein said strain is present in a quantity less than or equal to 30% by weight, compared with the total weight of the suspension, and wherein said micro-organism is coated with at least one coating comprising at least one vegetable lipid having a melting point of between 35°C and 75°C.
2. The suspension according to claim 1, wherein the oil consists of olive oil only; preferably it is olive oil mixed with maize oil and/or soya oil and/or linseed oil.
3. The suspension according to claims 1 or 2 , wherein said oily suspension furthermore comprises, in a quantity of between 0.1% and 15% by weight compared with the total weight of the suspension, at least one finely-divided food compound selected from the group comprising silica, silicon dioxide, silica gel, colloidal silica, precipitated silica, talc, magnesium silicate, magnesium oxide, magnesium carbonate, calcium silicate, lecithin, mono- or di-glycerids such as glyceril monostearate, glyceril monooleate, plurol-oleic acid, starch, modified starches, Konjac gum, xanthan gum, gellan gum and carrageenan.
4. The suspension according to any of claims 1-3, wherein said oily suspension furthermore comprises, in a quantity of between 0.5% and 25% by weight, compared with the total weight of the suspension, at least one prebiotic fibre and/or at least one bifidogenic carbohydrate selected from among inulin, fructo-oligosaccharides (FOS) , galacto- and transgalacto- oligosaccharides (GOS and TOS) , gluco-oligosaccharides (GOSoO , xylo-oligosaccharides (XOS) , chitosan-oligosaccharides (COS) , soya-oligosaccharides (SOS) , isomalto-oligosaccharides (IMOS), maltodextrin, resistant starch, pectin, psyllium, arabino- galactanes, gluco-mannanes , galacto-mannanes , xylanes, lactosaccharose, lactulose, lactitol, acacia fibre, carruba fibre, oat fibre, bamboo fibre and citrus fibre.
5. The suspension according to claim 4, wherein said at least one fibre and said at least one carbohydrate are selected from among gluco-oligosaccharides (GOSα) , fructo-oligosaccharides (FOS) , inulin and/or maltodextrin.
6. The suspension according to any of claims 1-5, wherein said vegetable lipid has a melting point comprised from 45°C to 65°C.
7. The suspension according to claim 6, wherein said vegetable lipid has a melting point comprised from 500C to 600C.
8. The suspension according to any of claims 1-7, wherein said strain of micro-organism is coated with a single lipid coating.
9. The suspension according to claim 8, wherein said lipid coating consists of polyglyceryl-6-distearate, preferably in a ratio by weight of micro-organisms: lipid coating of 50:50 or 40:60.
10. The suspension according to any of claims 1-9, wherein said strain of micro-organism is coated with a first lipid coating and a second lipid coating.
11. The suspension according to claim 10, wherein the first lipid coating consists of a hydrogenated palm fat and the second lipid coating consists of a glycerol dipalmitostearate, preferably in a ratio by weight of 3:1.
12. The suspension according to one of claims 1-11 for use as a medicament for the treatment of intestinal disturbances such as for example colic in paediatric patients.
13. Use of at least one strain of micro-organisms selected from the group consisting of the species according to claim 1, for the preparation of a suspension in accordance with any of claims 1-12, for the treatment of intestinal disturbances such as for example colic in paediatric patients.
14. Use according to claim 13, wherein said micro-organism is coated with a single lipid coating.
15. Use according to claim 14, wherein said lipid coating consists of polyglyceryl-6-distearate, preferably in a ratio by weight of micro-organisms: lipid coating of 50:50 or 40:60.
16. Use according to claim 13, wherein said strain of microorganism is coated with a first lipid coating and a second lipid coating.
17. Use according to claim 16, wherein said first lipid coating consists of a hydrogenated palm fat and the second lipid coating consists of a glycerol dipalmitostearate, preferably in a ratio by weight of 3:1. TABLE 1
No. Name Filing number Filing date Depositor
1 Streptococcus PROBIOTICAL
LMG P-18383 5.05.1998 thermophilics B39 S.p.A.
2 Streptococcus PROBIOTICAL
LMG P- 18384 5.05.1998 thermophilus T003 S.p.A.
3 Lactobacillus pentosus 9/1
LMG P-21019 16.10.2001 MOFIN S.R.L. ei
4 Lactobacillus plantarum
LMG P-21020 16.10.2001 MOFIN S.R.L. 776/1 bi
5 Lactobacillus plantarum
LMG P-21021 16.10.2001 MOFIN S.R.L. 476LL 20 bi
6 Lactobacillus plantarum
LMG P-21022 16.10.2001 MOHN S.R.L. PR ci
7 Lactobacillus plantarum
LMG P-21023 16.10.2001 MOFIN S.R.L. 776/2 hi
8 Lactobacillus casei ssp. PROBIOTICAL
LMG P-21380 31.01.2002 paracasei 181A/3 aiai S.p.A.
Lactobacillus belonging to
PROBIOTICAL the acidophilus group LMG P-21381 31.01.2002
S.p.A. 192A/1 aiai
10 Bifidobacterium longum PROBIOTICAL
LMG P-21382 31.01.2002 175 A/1 aiai S.p.A.
11 Bifidobacterium breve PROBIOTICAL
LMG P-21383 31.01.2002 195 A/1 aid S.p.A.
12 Bifidobacterium lactis PROBIOTICAL
LMG P-21384 31.01.2002 32A/3 aiai S.p.A.
13 Lactobacillus plantarum
LMG P-21385 31.01.2002 MOFIN S.R.L. 501/2 gi
14 Lactococcus lactis ssp.
LMG P-21387 15.03.2002 MOFIN S.R.L. lactis 501/4 hi
15 Lactococcus lactis ssp.
LMG P-21388 31.01.2002 MOHN S.R.L. lactis 501/4 ci
16 Lactobacillus plantarum
LMG P-21389 15.03.2002 MOFIN S.R.L. 501/4 Ii
17 Streptococcus DSM 16506 18.06.2004 PROBIOTICAL thermophilics GBl S.P.A.
Streptococcus PROBIOTICAL
DSM 16507 18.06.2004 thermophilus GB5 S.P.A.
Bifidobacterium longum PROBIOTICAL
DSM 16603 20.07.2004 BL 03 S.P.A.
Bifidobacterium breve BR PROBIOTICAL
DSM 16604 20.07.2004 03 S.P.A.
Lactobacillus casei ssp. PROBIOTICAL
DSM 16605 20.07.2004 rhamnosus LR 04 S.P.A.
Lactobacillus delbrueckii PROBIOTICAL
DSM 16606 20.07.2004 ssp. bulgaricus LDB 01 S.P.A.
Lactobacillus delbrueckii PROBIOTICAL
DSM 16607 20.07.2004 ssp. bulgaricus LDB 02 S.P.A.
Streptococcus PROBIOTICAL
DSM 16590 20.07.2004 thermophilus Y02 S.P.A.
Streptococcus PROBIOTICAL
DSM 16591 20.07.2004 thermophilus Y03 ■ S.P.A.
Streptococcus PROBIOTICAL
DSM 16592 20.07.2004 thermophilus Y04 S.P.A.
Streptococcus PROBIOTICAL
DSM 16593 20.07.2004 thermophilus Y05 S.P.A.
Bifidobacterium PROBIOTICAL
DSM 16594 21.07.2004 adolescentis BA 03 S.P.A.
Bifidobacterium PROBIOTICAL
DSM 16595 21.07.2004 adolescentis BA 04 S.P.A.
Bifidobacterium breve BR PROBIOTICAL
DSM 16596 21.07.2004 04 S.P.A. Bifidobacterium
PROBIOTICAL pseudocatenulatum DSM 16597 21.07.2004 S.P.A. BP Ol
Bifidobacterium
PROBIOTICAL pseudocatenulatum DSM 16598 21.07.2004 S.P.A. BP 02
Staphylococcus xylosus PROBIOTICAL
DSM 17102 01.02.2005 SX Ol S.P.A.
Bifidobacterium PROBIOTICAL
DSM 17103 01.02.2005 adolescentis BA 02 S.P.A.
Lactobacillus plantarum DSM 17104 01.02.2005 PROBIOTICAL LP 07 S.P.A.
Streptococcus PROBIOTICAL
DSM 17843 21.12.2005 thermophilus YO8 S.P.A.
Streptococcus PROBIOTICAL
DSM 17844 21.12.2005 thermophilus YO9 S.P.A.
Streptococcus PROBIOTICAL
DSM 17845 21.12.2005 thermophilus YOlOO S.P.A.
Lactobacillus fermentum PROBIOTICAL
DSM 18295 24.05.2006 LF06 S.P.A.
Lactobacillus fermentum PROBIOTICAL
DSM 18296 24.05.2006 LF07 S.P.A.
Lactobacillus fermentum PROBIOTICAL
DSM 18297 24.05.2006 LF08 S.P.A.
Lactobacillus fermentum PROBIOTICAL
DSM 18298 24.05.2006 LF09 S.P.A.
Lactobacillus gasseri PROBIOTICAL
DSM 18299 24.05.2006 LGSOl S.P.A.
Lactobacillus gasseri PROBIOTICAL
DSM 18300 24.05.2006 LGS02 S.P.A.
Lactobacillus gasseri PROBIOTICAL
DSM 18301 24.05.2006 LGS03 S.P.A.
Lactobacillus gasseri PROBIOTICAL
DSM 18302 24.05.2006 LGS04 S.P.A.
Bifidobacterium PROBIOTICAL
DSM 18350 15.06.2006 adolescentis El-3 S.P.A.
Bifidobacterium PROBIOTICAL
DSM 18351 15.06.2006 adolescentis El- 15 S.P.A.
Bifidobacterium PROBIOTICAL
DSM 18352 15.06.2006 adolescentis EI- 18 S.P.A.
Bifidobacterium PROBIOTICAL
DSM 18353 15.06.2006 catenulatum EI-20 S.P.A.
Streptococcus
DSM 18613 13.09.2006 MOFIN S.R.L. thermophilus FRai
Streptococcus DSM 18614 13.09.2006 MOFIN S.R.L. thermophilus LB2bi
Streptococcus DSM 18615 13.09.2006 MOFIN S.R.L. thermophilus LRci
Streptococcus DSM 18616 13.09.2006 MOFIN S.R.L. thermophilus FP4
Streptococcus DSM 18617 13.09.2006 MOFIN S.R.L. thermophilus ZZ5F8
Streptococcus DSM 18618 13.09.2006 MOFIN S.R.L. thermophilus TEO4
Streptococcus DSM 18619 13.09.2006 MOFIN S.R.L. thermophilus S lei
Streptococcus DSM 18620 13.09.2006 MOFIN S.R.L. thermophilus 641bi
Streptococcus DSM 18621 13.09.2006 MOFIN S.R.L. thermophilus 277A/lai
Streptococcus DSM 18622 13.09.2006 MOFIN S.R.L. thermophilus 277A/2ai
Streptococcus DSM 18623 13.09.2006 MOFIN S.R.L. thermophilus IDCIl
Streptococcus DSM 18624 13.09.2006 MOFIN S.R.L. thermophilus ML3di
Streptococcus DSM 18625 13.09.2006 MOFIN S.R.L. thermophilus TEO3
Streptococcus DSM 19057 21.02.2007 MOFIN S.R.L. thermophilus G62
Streptococcus DSM 19058 21.02.2007 MOFIN S.R.L. thermophilus Gl 192
Streptococcus DSM 19059 21.02.2007 MOFIN S.R.L. thermophilus GBl 8
Streptococcus DSM 19060 21.02.2007 MOFIN S.R.L. thermophilus CCR21
Streptococcus DSM 19061 21.02.2007 MOFIN S.R.L. thermophilus G92
Streptococcus DSM 19062 21.02.2007 MOFIN S.R.L. thermophilus G69
Streptococcus DSM 19063 21.02.2007 PROBIOTICAL thermophilus YO 10 S.P.A.
Streptococcus DSM 19064 21.02.2007 PROBIOTICAL thermophilus YO 11 S.P.A.
Streptococcus DSM 19065 21.02.2007 PROBIOTICAL thermophilus YO 12 S.P.A.
Streptococcus DSM 19066 21.02.2007 PROBIOTICAL thermophilics YO 13 S.P.A.
74 Weissella ssp. DSM 19067 21.02.2007 PROBIOTICAL WSP Ol S.P.A.
75 Weissella ssp. DSM 19068 21.02.2007 PROBIOTICAL WSP 02 S.P.A.
76 Weissella ssp. DSM 19069 21.02.2007 PROBIOTICAL WSP 03 S.P.A.
77 Lactobacillus plantarum DSM 19070 21.02.2007 PROBIOTICAL LP 09 S.P.A.
78 Lactococcus lactis DSM 19072 21.02.2007 PROBIOTICAL NS Ol S.P.A.
79 Lactobacillus plantarum DSM 19071 21.02.2007 PROBIOTICAL LP lO S.P.A.
80 Lactobacillus fermentum DSM 19187 20.03.2007 PROBIOTICAL LF lO S.P.A.
81 Lactobacillus fermentum DSM 19188 20.03.2007 PROBIOTICAL LF I l S.P.A.
82 Lactobacillus casei ssp. DSM 19739 27.09.2007 PROBIOTICAL rhamnosus LR 05 S.P.A.
83 Bifidobacterium bifidum DSM 19818 30.10.2007 PROBIOTICAL BBOl S.P.A.
84 Lactobacillus delbrueckii DSM 19948 28.11.2007 PROBIOTICAL LD Ol S.P.A.
85 Lactobacillus delbrueckii DSM 19949 28.1 1.2007 PROBIOTICAL LD 02 S.P.A.
86 Lactobacillus delbrueckii DSM 19950 28.1 1.2007 PROBIOTICAL LD 03 S.P.A.
87 Lactobacillus delbrueckii DSM 19951 28.11.2007 PROBIOTICAL LD 04 S.P.A.
88 Lactobacillus delbrueckii DSM 19952 28.11.2007 PROBIOTICAL LD 05 S.P.A.
89 Bifidobacterium DSM 21444 13.05.2008 PROBIOTICAL pseudocatenulatum B660 S.P.A.
90 Lactobacillus acidophilus DSM 21717 06.08.2008 PROBIOTICAL LA 02 S.P.A.
91 Lactobacillus paracasei DSM 21718 06.08.2008 PROBIOTICAL LPC 08 S.P.A.
92 Lactobacillus pentosus DSM 21980 14.11.2008 PROBIOTICAL LPS Ol S.P.A.
93 Lactobacillus rhamnosus DSM 21981 14.11.2008 PROBIOTICAL LR 06 S.P.A.
94 Lactobacillus salivarius DSM 22775 23.07.2009 PROBIOTICAL LSOl S.P.A.
95 Lactobacillus salivarius DSM 22776 23.07.2009 PROBIOTICAL LS06 S.P.A.
96 Bifidobacterium bifidum DSM 22892 28.08.2009 PROBIOTICAL BBOl S.P.A.
97 Bifidobacterium bifidum DSM 22893 28.08.2009 PROBIOTICAL S.P.A.
98 Bifidobacterium bifidum DSM 22894 28.08.2009 PROBIOTICAL BB03 S.P.A.
99 Bifidobacterium lactis DSM 23032 13.10.2009 PROBIOTICAL BS05 S.P.A.
100 Lactobacillus acidophilus DSM 23033 13.10.2009 PROBIOTICAL LA06 S.P.A.
101 Lactobacillus brevis DSM 23034 13.10.2009 PROBIOTICAL LBROl S.P.A.
102 Bifidobacterium DSM 23224 12.01.2010 PROBIOTICAL animalis/lactis BS06 S.P.A.
103 Bifidobacterium longum DSM 23234 12.01.2010 PROBIOTICAL BL05 S.P.A.
104 Bifidobacterium longum DSM 23233 12.01.2010 PROBIOTICAL BL04 S.P.A.
TABLE 2
Figure imgf000021_0001
TABLE 3
Figure imgf000021_0002
PCT/IB2010/000486 2009-03-09 2010-03-09 Oily suspension containing probiotic bacteria for paediatric uses Ceased WO2010103374A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2010222618A AU2010222618B2 (en) 2009-03-09 2010-03-09 Oily suspension containing probiotic bacteria for paediatric uses
CA2754612A CA2754612A1 (en) 2009-03-09 2010-03-09 Oily suspension containing probiotic bacteria for paediatric use
US13/255,176 US20120058095A1 (en) 2009-03-09 2010-03-09 Oily suspension containing probiotic bacteria for paediatric uses
EP10716405A EP2405894A2 (en) 2009-03-09 2010-03-09 Oily suspension containing probiotic bacteria for paediatric uses
JP2011553543A JP2012519727A (en) 2009-03-09 2010-03-09 Oily suspension containing probiotic bacteria for administration to children
CN2010800162523A CN102438589A (en) 2009-03-09 2010-03-09 Oily suspension containing probiotic bacteria for paradiatric uses
BRPI1009208A BRPI1009208A2 (en) 2009-03-09 2010-03-09 "oil suspension containing probiotic bacteria for pediatric use"
RU2011139210/15A RU2011139210A (en) 2009-03-09 2010-03-09 OIL SUSPENSION CONTAINING PROBIOTIC BACTERIA FOR PEDIATRIC USE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2009A000104A IT1400821B1 (en) 2009-03-09 2009-03-09 OIL SUSPENSION CONTAINING PROBIOTIC BACTERIA FOR PEDIATRIC USE
ITRM2009A000104 2009-03-09

Publications (4)

Publication Number Publication Date
WO2010103374A2 true WO2010103374A2 (en) 2010-09-16
WO2010103374A3 WO2010103374A3 (en) 2011-03-31
WO2010103374A8 WO2010103374A8 (en) 2011-10-27
WO2010103374A9 WO2010103374A9 (en) 2012-01-19

Family

ID=41095460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/000486 Ceased WO2010103374A2 (en) 2009-03-09 2010-03-09 Oily suspension containing probiotic bacteria for paediatric uses

Country Status (11)

Country Link
US (1) US20120058095A1 (en)
EP (1) EP2405894A2 (en)
JP (1) JP2012519727A (en)
KR (1) KR20110126753A (en)
CN (1) CN102438589A (en)
AU (1) AU2010222618B2 (en)
BR (1) BRPI1009208A2 (en)
CA (1) CA2754612A1 (en)
IT (1) IT1400821B1 (en)
RU (1) RU2011139210A (en)
WO (1) WO2010103374A2 (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011073769A3 (en) * 2009-12-16 2011-11-24 Probiotical S.P.A. Conjugated linoleic acid-producing strains of probiotic bacteria and use thereof for the preparation of a food, dietetic or pharmaceutical composition
ITMI20102235A1 (en) * 2010-12-03 2012-06-04 Probiotical Spa STRAINS OF PROBIOTIC BACTERIA PRODUCERS OF CONJUGATE OF LINOLEIC ACID AND THEIR USE FOR THE PREPARATION OF A FOOD, DIETHETIC OR PHARMACEUTICAL COMPOSITION.
DE102011009798A1 (en) * 2011-01-31 2012-08-02 Merz Pharma Gmbh & Co. Kgaa Balneological lipid-containing probiotic preparations for cosmetic / dermatological / medical applications
WO2012123770A1 (en) * 2011-03-17 2012-09-20 Probiotical S.P.A. Probiotic bacteria having antioxidant activity and use thereof
ITMI20110906A1 (en) * 2011-05-20 2012-11-21 Probiotical Spa COMPOSITION INCLUDING LACTIC BACTERIA AND / OR BIFIDOBACTERIES FOR UNDER-CAPS OF BOTTLES OR BOTTLES OR CAPSULES.
ITMI20120131A1 (en) * 2012-02-01 2013-08-02 Probiotical Spa MULTILAYER MICROCAPSULATED PROBIOTIC BACTERIA, THEIR PRODUCTION AND USE
ITRM20120084A1 (en) * 2012-03-07 2013-09-08 Aboca Spa Societa Agricola PREBIOTIC MIXTURE.
US8754126B2 (en) 2010-12-29 2014-06-17 Abbott Laboratories Methods for improving tolerance, digestion, and lipid soluble nutrient absorption in an infant, toddler, or child
JP2014531430A (en) * 2011-09-09 2014-11-27 ジョヴァンニ・モーニャＧｉｏｖａｎｎｉ ＭＯＧＮＡ Composition comprising N-acetylcysteine and / or microencapsulated gastroprotective lysozyme in combination with probiotic bacteria capable of repairing the gastric barrier effect lost during gastric acidity drug treatment
WO2016030440A1 (en) * 2014-08-28 2016-03-03 Vesale Pharma Sa Oily formulation comprising at least one probiotic bacterium
US9427012B2 (en) 2010-08-10 2016-08-30 R.P. Scherer Technologies, Llc Process of manufacturing a stable softgel capsule containing microencapsulated probiotic bacteria
US9492377B2 (en) 2011-01-28 2016-11-15 Probiotical S.P.A. Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
US9498503B2 (en) 2010-03-08 2016-11-22 Probiotical S.P.A. Composition comprising probiotic bacteria for use in the treatment of immune disorders
WO2018029629A1 (en) * 2016-08-10 2018-02-15 Probiotical S.P.A. Composition for use in the treatment of major depressive disorder
US9925224B2 (en) 2011-05-09 2018-03-27 Probiotical S.P.A. Bacterial strains belonging to the genus bifidobacterium for use in the treatment of hypercholesterolaemia
US10286017B2 (en) 2011-05-09 2019-05-14 Probiotical S.P.A. Probiotic bacterial strains and symbiotic composition containing the same intended for infant food
US10384847B2 (en) 2011-09-23 2019-08-20 Probiotical North America Inc. Material impermeable to humidity and oxygen for packaging dietary products, cosmetics and medicinal specialities
US10709744B1 (en) * 2019-03-28 2020-07-14 Mybiotics Pharma Ltd. Probiotic biofilm suppositories
US10982184B2 (en) 2011-05-09 2021-04-20 Probiotical S.P.A. Bacterial strains capable of metabolizing oxalates
IT201900020805A1 (en) * 2019-11-11 2021-05-11 Probiotical Spa Gastro-protected granular bacteria with coating matrix in crystalline form, process for their preparation and their compositions
US11110136B2 (en) 2013-05-14 2021-09-07 Probiotical S.P.A. Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis
CN113766923A (en) * 2019-03-28 2021-12-07 迈彼欧提克斯制药有限公司 Probiotic biofilm composition and preparation method thereof
US11541082B2 (en) * 2017-06-05 2023-01-03 Probi Ab Microbial compositions
US11679136B2 (en) 2016-05-25 2023-06-20 Mybiotics Pharma Ltd. Composition and methods for microbiota therapy
US11680257B2 (en) 2015-05-11 2023-06-20 Mybiotics Pharma Ltd. Systems and methods for growing a biofilm of probiotic bacteria on solid particles for colonization of bacteria in the gut
US11679135B2 (en) 2017-12-19 2023-06-20 Probiotical S.P.A. Composition for use in the treatment and/or improvement of sleep and mood disorders
US11998578B2 (en) 2017-12-19 2024-06-04 Probiotical S.P.A. Composition for use in the treatment and/or improvement of sleep and mood disorders
IT202300026925A1 (en) 2023-12-18 2025-06-18 Labomar S P A IMPROVED COMPOSITIONS OF PROBIOTIC DISPERSION IN OILY SUSPENSIONS
US12343363B2 (en) 2016-03-24 2025-07-01 Probiotical S.P.A. Lactic acid bacterial composition for the treatment of bacterial vaginal infections by Gardnerella vaginalis and, if present, of concurrent fungal infections

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265351B2 (en) * 2013-08-09 2019-04-23 Ab-Biotics, S.A. Probiotic for infantile colic
CN103689595A (en) * 2013-12-12 2014-04-02 天津科技大学 Soft lactic acid bacteria capsule and preparation method thereof
JP6468633B2 (en) * 2014-10-03 2019-02-13 富士カプセル株式会社 Three-layer structure seamless capsule
CN105266036A (en) * 2015-11-17 2016-01-27 黑龙江省科学院微生物研究所 Preparation method of natto soft capsule health-care food having intestinal conditioning and immunity adjusting functions
CN105456563A (en) * 2015-12-25 2016-04-06 天津天狮生物发展有限公司 Composition for improving intestinal functions
CN105560211B (en) * 2015-12-30 2019-06-14 大连医诺生物股份有限公司 Optimize the microcapsule formulation of embedding
US9999640B2 (en) * 2016-02-02 2018-06-19 University Of Dammam Microencapsulated probiotic bacteria
IT201700011632A1 (en) * 2017-02-02 2018-08-02 Farm Procemsa S P A PROBIOTIC COMPOSITION
WO2018207744A1 (en) * 2017-05-08 2018-11-15 富士シリシア化学株式会社 In vivo transportation carrier, complex using same, and in vivo transportation method
JP6640966B2 (en) * 2018-12-05 2020-02-05 富士カプセル株式会社 Three-layer seamless capsule
EP3955941A4 (en) * 2019-04-17 2023-04-19 NUtech Ventures COMPOSITIONS COMPRISING NOVEL MICROBES WITH ENHANCED PERSISTENCE, SYNERGIC COMBINATIONS OF NOVEL MICROBES AND PREBIOTICS, AND METHODS OF ISOLATING SUCH MICROBES
AU2020366736B2 (en) * 2019-10-17 2023-07-20 Morinaga Milk Industry Co., Ltd. Composition, production method, and usage
JP7222548B2 (en) * 2019-12-26 2023-02-15 富士カプセル株式会社 Three-layer structure seamless capsule
RU2765382C1 (en) * 2020-12-30 2022-01-28 Федеральное государственное бюджетное образовательное учреждение высшего образования «Воронежский государственный университет инженерных технологий» (ФГБОУ ВО «ВГУИТ») Method for producing probiotic food emulsion
CN113575756A (en) * 2021-07-09 2021-11-02 内蒙古普泽动保生物技术有限公司 Oily suspension containing probiotics and preparation method thereof
WO2023049693A2 (en) 2021-09-24 2023-03-30 Johnson & Johnson Consumer Inc. Dosage forms for the delivery of a probiotic
US20230127202A1 (en) * 2021-10-26 2023-04-27 Cornell University Long-term probiotic bacterial storage at ambient temperature
CN115088844B (en) * 2022-07-14 2024-05-24 河北益存生物科技有限公司 Lactic acid bacteria oil drop and preparation method thereof
CN116649575B (en) * 2023-05-16 2025-02-07 汤臣倍健股份有限公司 Oil-based composition and application thereof, probiotic drops and preparation method thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH637297A5 (en) * 1978-12-05 1983-07-29 Nestle Sa MICROBALL COMPRISING A MICROORGANISM AND ITS MANUFACTURING METHOD.
US4657784A (en) * 1986-03-10 1987-04-14 Ecolab Inc. Process for encapsulating particles with at least two coating layers having different melting points
US6251478B1 (en) * 1999-12-22 2001-06-26 Balchem Corporation Sensitive substance encapsulation
FR2806307B1 (en) * 2000-03-20 2002-11-15 Mane Fils V SOLID SCENTED PREPARATION IN THE FORM OF MICROBALLS AND USE OF SAID PREPARATION
US7214370B2 (en) * 2000-12-18 2007-05-08 Probiohealth, Llc Prebiotic and preservative uses of oil-emulsified probiotic encapsulations
US20030143262A1 (en) * 2001-12-13 2003-07-31 Brusk Ulla Forsgren Hygiene tissue
CA2503510C (en) * 2002-09-26 2014-12-02 Probiohealth, Llc Prebiotic and preservative uses of oil-emulsified probiotic encapsulations
US20100055083A1 (en) * 2006-10-18 2010-03-04 Ray Edward Kowalski Encapsulation of heat and moisture sensitive substances
EP2173856A1 (en) * 2007-06-28 2010-04-14 Chr. Hansen A/S Treatment of cell suspension
NZ555022A (en) * 2007-11-07 2010-09-30 Encoate Holdings Ltd Stabilisation of dried biological material with oil and biopolymer

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011073769A3 (en) * 2009-12-16 2011-11-24 Probiotical S.P.A. Conjugated linoleic acid-producing strains of probiotic bacteria and use thereof for the preparation of a food, dietetic or pharmaceutical composition
US10688138B2 (en) * 2009-12-16 2020-06-23 Alce North America, Inc. Conjugated linoleic acid-producing strains of probiotic bacteria and use thereof for the preparation of a food, dietetic or pharmaceutical composition
US20180104286A1 (en) * 2009-12-16 2018-04-19 Alce North America, Inc. Conjugated linoleic acid-producing strains of probiotic bacteria and use thereof for the preparation of a food, dietetic or pharmaceutical composition
US9833484B2 (en) * 2009-12-16 2017-12-05 Alce North America, Inc. Conjugated linoleic acid-producing strains of probiotic bacteria and use thereof for the preparation of a food, dietetic or pharmaceutical composition
US20150023925A1 (en) * 2009-12-16 2015-01-22 Giovanni Mogna Conjugated linoleic acid-producing strains of probiotic bacteria and use thereof for the preparation of a food, dietetic or pharmaceutical composition
US9931363B2 (en) 2010-03-08 2018-04-03 Probiotical S.P.A. Composition comprising probiotic bacteria for use in the treatment of immune disorders
AU2011225798B2 (en) * 2010-03-08 2017-02-02 Probiotical S.P.A. Composition comprising probiotic bacteria for use in the treatment of immune disorders
US9498503B2 (en) 2010-03-08 2016-11-22 Probiotical S.P.A. Composition comprising probiotic bacteria for use in the treatment of immune disorders
US9427012B2 (en) 2010-08-10 2016-08-30 R.P. Scherer Technologies, Llc Process of manufacturing a stable softgel capsule containing microencapsulated probiotic bacteria
ITMI20102235A1 (en) * 2010-12-03 2012-06-04 Probiotical Spa STRAINS OF PROBIOTIC BACTERIA PRODUCERS OF CONJUGATE OF LINOLEIC ACID AND THEIR USE FOR THE PREPARATION OF A FOOD, DIETHETIC OR PHARMACEUTICAL COMPOSITION.
US8877812B2 (en) * 2010-12-29 2014-11-04 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome in an infant, toddler, or child
US9433586B2 (en) 2010-12-29 2016-09-06 Abbott Laboratories Methods of improving tolerance related to feeding in an infant, toddler, or child
US8754126B2 (en) 2010-12-29 2014-06-17 Abbott Laboratories Methods for improving tolerance, digestion, and lipid soluble nutrient absorption in an infant, toddler, or child
US9844517B2 (en) 2010-12-29 2017-12-19 Abbott Laboratories Nutritional products including a novel fat system including fatty acids
US9078847B2 (en) 2010-12-29 2015-07-14 Abbott Laboratories Nutritional products including a novel fat system including monoglycerides
US9078846B2 (en) 2010-12-29 2015-07-14 Abbott Laboratories Nutritional products including monoglycerides and fatty acids
US9446005B2 (en) 2010-12-29 2016-09-20 Abbott Laboratories Methods for improving tolerance, digestion, and lipid soluble nutrient absorption in an infant, toddler, or child
US9492377B2 (en) 2011-01-28 2016-11-15 Probiotical S.P.A. Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
DE102011009798A1 (en) * 2011-01-31 2012-08-02 Merz Pharma Gmbh & Co. Kgaa Balneological lipid-containing probiotic preparations for cosmetic / dermatological / medical applications
WO2012104025A2 (en) 2011-01-31 2012-08-09 Merz Pharma Gmbh & Co. Kgaa Balneotherapeutic lipid-containing probiotic preparations and their applications
DE102011009798B4 (en) * 2011-01-31 2015-03-05 Merz Pharma Gmbh & Co. Kgaa Balneological lipid-containing probiotic preparations for cosmetic / dermatological / medical applications
CN103582486A (en) * 2011-03-17 2014-02-12 益生菌股份公司 Probiotic bacteria having antioxidant activity and use thereof
US20140065116A1 (en) * 2011-03-17 2014-03-06 Giovanni Mogna Probiotic bacteria having antioxidant activity and use thereof
WO2012123770A1 (en) * 2011-03-17 2012-09-20 Probiotical S.P.A. Probiotic bacteria having antioxidant activity and use thereof
JP2014508186A (en) * 2011-03-17 2014-04-03 プロバイオティカル・ソシエタ・ペル・アチオニ Probiotic bacteria having antioxidant activity and their use
CN103582486B (en) * 2011-03-17 2016-11-16 益生菌股份公司 Probiotic bacteria with antioxidant activity and application thereof
US9925224B2 (en) 2011-05-09 2018-03-27 Probiotical S.P.A. Bacterial strains belonging to the genus bifidobacterium for use in the treatment of hypercholesterolaemia
US10982184B2 (en) 2011-05-09 2021-04-20 Probiotical S.P.A. Bacterial strains capable of metabolizing oxalates
US10286017B2 (en) 2011-05-09 2019-05-14 Probiotical S.P.A. Probiotic bacterial strains and symbiotic composition containing the same intended for infant food
ITMI20110906A1 (en) * 2011-05-20 2012-11-21 Probiotical Spa COMPOSITION INCLUDING LACTIC BACTERIA AND / OR BIFIDOBACTERIES FOR UNDER-CAPS OF BOTTLES OR BOTTLES OR CAPSULES.
US10028982B2 (en) 2011-09-09 2018-07-24 Probiotical North America Inc. Composition comprising N-acetylcysteine and/or microencapsulated gastroprotected lysozyme in association with probiotic bacteria capable of restoring the stomach's own barrier effect which is lost during the pharmacological treatment of gastric hyperacidity
JP2014531430A (en) * 2011-09-09 2014-11-27 ジョヴァンニ・モーニャＧｉｏｖａｎｎｉ ＭＯＧＮＡ Composition comprising N-acetylcysteine and / or microencapsulated gastroprotective lysozyme in combination with probiotic bacteria capable of repairing the gastric barrier effect lost during gastric acidity drug treatment
US10384847B2 (en) 2011-09-23 2019-08-20 Probiotical North America Inc. Material impermeable to humidity and oxygen for packaging dietary products, cosmetics and medicinal specialities
ITMI20120131A1 (en) * 2012-02-01 2013-08-02 Probiotical Spa MULTILAYER MICROCAPSULATED PROBIOTIC BACTERIA, THEIR PRODUCTION AND USE
WO2013114185A1 (en) * 2012-02-01 2013-08-08 Probiotical S.P.A. Multilayer microincapsulated probiotic bacteria
US10738274B2 (en) 2012-02-01 2020-08-11 Probiotical North America Inc. Multilayer microencapsulated probiotic bacteria
WO2013132456A1 (en) * 2012-03-07 2013-09-12 Aboca Societa' S.P.A. Societa' Agricola Prebiotic mixture
ITRM20120084A1 (en) * 2012-03-07 2013-09-08 Aboca Spa Societa Agricola PREBIOTIC MIXTURE.
US9907827B2 (en) 2012-03-07 2018-03-06 Aboca S.P.A. Societá Agricola Prebiotic mixture
US11110136B2 (en) 2013-05-14 2021-09-07 Probiotical S.P.A. Composition comprising lactic acid bacteria for use in the preventive and/or curative treatment of recurrent cystitis
WO2016030440A1 (en) * 2014-08-28 2016-03-03 Vesale Pharma Sa Oily formulation comprising at least one probiotic bacterium
BE1024031B1 (en) * 2014-08-28 2017-10-31 Vesale Pharma Sa OIL FORMULATION COMPRISING AT LEAST ONE PROBIOTIC BACTERIUM.
US11680257B2 (en) 2015-05-11 2023-06-20 Mybiotics Pharma Ltd. Systems and methods for growing a biofilm of probiotic bacteria on solid particles for colonization of bacteria in the gut
US12343363B2 (en) 2016-03-24 2025-07-01 Probiotical S.P.A. Lactic acid bacterial composition for the treatment of bacterial vaginal infections by Gardnerella vaginalis and, if present, of concurrent fungal infections
US11679136B2 (en) 2016-05-25 2023-06-20 Mybiotics Pharma Ltd. Composition and methods for microbiota therapy
US11298384B2 (en) 2016-08-10 2022-04-12 Probiotical S.P.A. Composition for use in the treatment of major depressive disorder
CN109789171A (en) * 2016-08-10 2019-05-21 波比奥泰克股份公司 For treating the composition of major depressive disorder
US11969449B2 (en) 2016-08-10 2024-04-30 Probiotical S.P.A. Composition for use in the treatment of major depressive disorder
WO2018029629A1 (en) * 2016-08-10 2018-02-15 Probiotical S.P.A. Composition for use in the treatment of major depressive disorder
US11541082B2 (en) * 2017-06-05 2023-01-03 Probi Ab Microbial compositions
US11679135B2 (en) 2017-12-19 2023-06-20 Probiotical S.P.A. Composition for use in the treatment and/or improvement of sleep and mood disorders
US11998578B2 (en) 2017-12-19 2024-06-04 Probiotical S.P.A. Composition for use in the treatment and/or improvement of sleep and mood disorders
CN113766923A (en) * 2019-03-28 2021-12-07 迈彼欧提克斯制药有限公司 Probiotic biofilm composition and preparation method thereof
US10709744B1 (en) * 2019-03-28 2020-07-14 Mybiotics Pharma Ltd. Probiotic biofilm suppositories
WO2021094952A1 (en) * 2019-11-11 2021-05-20 Probiotical S.P.A. Granular bacteria gastroprotected with a coating matrix in crystalline form, process for the preparation thereof and compositions thereof
IT201900020805A1 (en) * 2019-11-11 2021-05-11 Probiotical Spa Gastro-protected granular bacteria with coating matrix in crystalline form, process for their preparation and their compositions
IT202300026925A1 (en) 2023-12-18 2025-06-18 Labomar S P A IMPROVED COMPOSITIONS OF PROBIOTIC DISPERSION IN OILY SUSPENSIONS
WO2025133941A1 (en) * 2023-12-18 2025-06-26 Labomar S.P.A. Compositions for improving the dispersion of probiotics in oily suspensions

Also Published As

Publication number Publication date
CA2754612A1 (en) 2010-09-16
CN102438589A (en) 2012-05-02
KR20110126753A (en) 2011-11-23
JP2012519727A (en) 2012-08-30
IT1400821B1 (en) 2013-07-02
WO2010103374A8 (en) 2011-10-27
WO2010103374A9 (en) 2012-01-19
US20120058095A1 (en) 2012-03-08
AU2010222618B2 (en) 2015-03-19
EP2405894A2 (en) 2012-01-18
WO2010103374A3 (en) 2011-03-31
AU2010222618A1 (en) 2011-10-13
BRPI1009208A2 (en) 2016-03-08
ITRM20090104A1 (en) 2010-09-09
RU2011139210A (en) 2013-04-20

Similar Documents

Publication Publication Date Title
AU2010222618B2 (en) Oily suspension containing probiotic bacteria for paediatric uses
Liu et al. Incorporation of polysaccharides into sodium caseinate-low melting point fat microparticles improves probiotic bacterial survival during simulated gastrointestinal digestion and storage
EP2451300B2 (en) Heat resistant probiotic compositions and healthy food comprising them
JP6240386B2 (en) Probiotic stabilization
Zanjani et al. Microencapsulation of Lactobacillus casei with calcium alginate-resistant starch and evaluation of survival and sensory properties in cream-filled cake
EP2381799B1 (en) Chocolate flavoured probiotic supplement
RU2011150216A (en) CHILDREN'S NUTRIENT MIXTURES CONTAINING PROBIOTIC MICRO-ORGANISMS
EP2852393B1 (en) Compositions comprising probiotics and a complex beepollen/clay, preparation and uses in nutrition and therapy
JP2021521249A (en) Moisture resistant probiotic granules and their manufacturing method
Golnari et al. Comparative survival study of Bacillus coagulans and Enterococcus faecium microencapsulated in chitosan-alginate nanoparticles in simulated gastrointestinal condition
CA2628495A1 (en) Edible product containing ginseng polysaccharides and beneficial bacteria
CN117256859A (en) Beverages containing live probiotics and multi-layered dripping pills used
JP2004250338A (en) Useful live bacterium pharmaceutical preparation
JP2003012526A (en) Pharmaceutical preparation including useful live bacterium
CN114747769B (en) A kind of probiotic product and preparation method thereof
CN110279118B (en) Composite probiotic composition, composite probiotic freeze-dried powder capsule and preparation method
WO2022090474A1 (en) Microencapsulated microbial composition
Aghajania et al. Microencapsulation of probiotics in yogurt: A Review
Mandal et al. Diversification of probiotics through encapsulation technology
CN107897932A (en) A kind of symbiotic formulation
Sekhavatizadeh et al. Double-layer microencapsulation of Lacticaseibacillus rhamnosus using sodium alginate and nano-mucilages of Qodume Shirazi and Camelina sativa for probiotic goat milk dessert
Sbehat Layer-by-layer coating of single cell Lactobacillus rhamnosus GG to increases viability under simulated gastrointestinal conditions.
SALARIA PREPARATION OF PROBIOTIC ADJUNCT FOR INFANT FOOD FORMULATION
Ogorelec et al. J. Beganović, B. Kos, A. Leboš Pavunc, K. Habjanič
MANDAL MICROENCAPSULATION OF PROSIOTICS AND

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080016252.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10716405

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2754612

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011553543

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 3750/KOLNP/2011

Country of ref document: IN

Ref document number: 2010716405

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010222618

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2011139210

Country of ref document: RU

Kind code of ref document: A

Ref document number: 20117023818

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2010222618

Country of ref document: AU

Date of ref document: 20100309

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13255176

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1009208

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI1009208

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110909